Alnylam Pharmaceuticals, Inc. (ALNY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY)

ALNY 456.04

+1.5%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas who wrote (153)	1/20/2010 11:40:44 AM
From: idos	1 Recommendation Read Replies (1) of 166

It's a tough road for RNAi in the clinic. I think it's partly because there was a rush in to clinical trials that caused many programs to fail or be killed. The new lipidoid and lipid nanoparticles deliveries are more targeted and efficient and may also overcome some of the side effects due to lowering dosage. So long term, despite all hurdles, I still believe those that survive (like ALNY) will succeed in the clinic. The yawn is cause the latest findings are pre clinical and also cause many are disappointed and doubt the tech will ever work.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next